We evaluated the feasibility and effectiveness of the continuous subcutaneous insulin infusion (CSN) therapy as compared to conventional injection treatment (CIT) in a diabetes clinic in a one month randomized study of 42 type l diabetic patients. During the first month, the daily insulin dose was reduced by 44 % in patients who were treated with CSII compared with CIT (p<0.005). Blood glucose levels measured four times in a day (05, 11, 17 and 23 hours) were lower during CSII than CIT (p<0.001, p<0.001, p<0.001, p<0.001). The blood total glycosylated hemoglobin (HbA1) levels fell in the first month of CSII therapy compared to CIT (p<0.001). in the CSII group, serum total cholesterol (TC) low density lipoprotein cholesterol (LDL), very low density lipoprotein cholesterol (VLDL) and triglyceride (TG) levels were lower and high density lipoprotein cholesterol (HDL) levels were higher than in the CIT group (p<0.02, p<0.01, p<0.005, p<0.05). There were no ketoacidotic or hypoglycemic episodes, mechanical problems with the pump or needle-site infections in our study. These results indicate that CSII treatment is more effective than CIT on metabolic control in Type l Diabetes.
Keywords: Continuous subcutaneous insulin infusion, conventional injection treatment, metabolic control